# a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Source: https://onco.cc/trials/nct06166836/  
OnCo record `nct06166836` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IN10018 in advanced solid tumours, run by InxMed (Shanghai) Co., Ltd., active and no longer recruiting.

## Summary

a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors is a phase 1/2 interventional study registered as NCT06166836 by InxMed (Shanghai) Co., Ltd., with 140 participants enrolled, started 2022-10-12 and due to reach its primary completion in 2027-12-31. Interventions recorded: D1553 and IN10018（Ifebemtinib）.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06166836
- Phase: 1/2
- Setting: A Phase 1b/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 Combined With IN10018 in Subjects With Locally Advanced or Metastatic Solid Tumors With KRAS G12C Mutation
- Sponsor: InxMed (Shanghai) Co., Ltd.
- Enrolled: 140

## Sources

- ClinicalTrials.gov NCT06166836: https://clinicaltrials.gov/study/NCT06166836

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [IN10018](https://onco.cc/drugs/in10018/)
- companies: [InventisBio](https://onco.cc/companies/inventisbio/)

---
JSON: https://onco.cc/api/v1/entities/nct06166836.json